Sandbox vidit2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{| style="cellpadding=0; cellspacing= 0; width: 600px;" | {| style="cellpadding=0; cellspacing= 0; width: 600px;" | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug | | style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Drug'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Loading dose]]''' || style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''[[Maintenance dose]]''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Acute Setting''''' | ||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients without [[accessory pathway]]''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Esmolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''500 mcg/kg IV over 1 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''60 to 200 mcg/kg/min IV''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.15 mg/kg IV''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2.5 to 5 mg IV bolus over 2 min; up to 3 doses''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''5 to 15 mg/h IV''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.075 to 0.15 mg/kg IV over 2 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''NA''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control in patients with [[accessory pathway]]''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with [[heart failure]] and without [[accessory pathway]]''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIa Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''150 mg over 10 min''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 to 1 mg/min IV''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.25 mg IV each 2 h, up to 1.5 mg''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily IV or orally''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Non-Acute Setting and Chronic Maintenance Therapy''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart rate control''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metoprolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''25 to 100 mg twice a day, orally''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Propanolol]] (Class of recommendation I Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''80 to 240 mg daily in divided doses, orally''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Verapamil]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Diltiazem]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Same as maintenance dose''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''120 to 360 mg daily in divided doses; slow release available, orally''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Heart Rate Control in patients with heart failure and without accessory pathway''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Digoxin]] (Class of recommendation I Level of evidence B)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.5 mg by mouth daily''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''0.125 to 0.375 mg daily, orally''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amiodarone]] (Class of recommendation IIb Level of evidence C)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''800 mg daily for 1 wk, orally <br> 600 mg daily for 1 wk, orally <br> 400 mg daily for 4 to 6 wk, orally''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''200 mg daily, orally''''' | |||
|- | |- | ||
|} | |} | ||
Revision as of 16:33, 6 March 2014
| Drug | Loading dose | Maintenance dose |
| Acute Setting | ||
| Heart rate control in patients without accessory pathway | ||
| ▸ Esmolol (Class of recommendation I Level of evidence C) | ▸ 500 mcg/kg IV over 1 min | ▸ 60 to 200 mcg/kg/min IV |
| ▸ Propanolol (Class of recommendation I Level of evidence C) | ▸ 0.15 mg/kg IV | ▸ NA |
| ▸ Metoprolol (Class of recommendation I Level of evidence C) | ▸ 2.5 to 5 mg IV bolus over 2 min; up to 3 doses | ▸ NA |
| ▸ Diltiazem (Class of recommendation I Level of evidence B) | ▸ 0.25 mg/kg IV over 2 min | ▸ 5 to 15 mg/h IV |
| ▸ Verapamil (Class of recommendation I Level of evidence B) | ▸ 0.075 to 0.15 mg/kg IV over 2 min | ▸ NA |
| Heart rate control in patients with accessory pathway | ||
| ▸ Amiodarone (Class of recommendation IIa Level of evidence C) | ▸ 150 mg over 10 min | ▸ 0.5 to 1 mg/min IV |
| Heart Rate Control in patients with heart failure and without accessory pathway | ||
| ▸ Amiodarone (Class of recommendation IIa Level of evidence C) | ▸ 150 mg over 10 min | ▸ 0.5 to 1 mg/min IV |
| ▸ Digoxin (Class of recommendation I Level of evidence B) | ▸ 0.25 mg IV each 2 h, up to 1.5 mg | ▸ 0.125 to 0.375 mg daily IV or orally |
| Non-Acute Setting and Chronic Maintenance Therapy | ||
| Heart rate control | ||
| ▸ Metoprolol (Class of recommendation I Level of evidence C) | ▸ Same as maintenance dose | ▸ 25 to 100 mg twice a day, orally |
| ▸ Propanolol (Class of recommendation I Level of evidence C) | ▸ Same as maintenance dose | ▸ 80 to 240 mg daily in divided doses, orally |
| ▸ Verapamil (Class of recommendation I Level of evidence B) | ▸ Same as maintenance dose | ▸ 120 to 360 mg daily in divided doses; slow release available, orally |
| ▸ Diltiazem (Class of recommendation I Level of evidence B) | ▸ Same as maintenance dose | ▸ 120 to 360 mg daily in divided doses; slow release available, orally |
| Heart Rate Control in patients with heart failure and without accessory pathway | ||
| ▸ Digoxin (Class of recommendation I Level of evidence B) | ▸ 0.5 mg by mouth daily | ▸ 0.125 to 0.375 mg daily, orally |
| ▸ Amiodarone (Class of recommendation IIb Level of evidence C) | ▸ 800 mg daily for 1 wk, orally 600 mg daily for 1 wk, orally 400 mg daily for 4 to 6 wk, orally |
▸ 200 mg daily, orally |